Sumitomo Mitsui DS Asset Management Company Ltd Has $1.22 Million Holdings in United Therapeutics Corporation $UTHR

Sumitomo Mitsui DS Asset Management Company Ltd cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 3.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,239 shares of the biotechnology company’s stock after selling 165 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in United Therapeutics were worth $1,218,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $49,000. Brooklyn Investment Group raised its holdings in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $60,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on UTHR. Morgan Stanley decreased their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, September 4th. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Jefferies Financial Group raised their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Finally, Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $438.85.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $406.17, for a total value of $4,467,870.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $14,939,338.77. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $417.30, for a total transaction of $1,669,200.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $54,249. The trade was a 96.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 176,435 shares of company stock valued at $65,503,807 in the last 90 days. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

UTHR stock opened at $414.73 on Tuesday. The company has a fifty day moving average price of $331.90 and a two-hundred day moving average price of $311.38. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $436.95. The stock has a market cap of $18.71 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 6.37 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period last year, the firm earned $5.85 earnings per share. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.